ReviewReview
Open Access

Medication-overuse headache: clinical profile and management strategies

Khalid W. AlQuliti and Rakan M. Alhujeily
Neurosciences Journal January 2023, 28 (1) 13-18; DOI: https://doi.org/10.17712/nsj.2023.1.20220115

References

  1. 1.↵
    Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd ed. Sage Publishing; 2018. Available from: https://www.ichd-3.org/wp-content/uploads/2018/01/The-International-Classification-of-Headache-Disorders-3rd-Edition-2018.pdf
  2. 2.↵
    1. Horton BT,
    2. Peters GA.
    Clinical manifestations of excessive use of ergotamine preparations and management of withdrawal effect. Report of 52 cases. Headache 1963; 2: 214-217.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Dodick DW.
    Migraine. Lancet 2018; 391: 1315-1330.
    OpenUrlPubMed
  4. 4.↵
    1. Al-Quliti KW,
    2. Assaedi ES.
    New advances in prevention of migraine. Review of current practice and recent advances. Neurosciences (Riyadh) 2016; 21: 207-214.
    OpenUrl
  5. 5.↵
    1. Al-Quliti, KW,
    2. Alhujeily R,
    3. Aljarbou OM,
    4. Al-Rasheedi RS,
    5. Alrewaithi B.
    Knowledge, attitude, and practice among pharmacists for migraine management in Al-Madinah Al-Munawarah. Int J Med Dev Countries 2022; 6: 340-347.
    OpenUrl
  6. 6.↵
    1. Kulkarni GB,
    2. Mathew T,
    3. Mailankody P.
    Medication overuse headache. Neurol India 2021; 69: S76-S82.
    OpenUrl
  7. 7.↵
    1. Aurora SK,
    2. Brin MF.
    Chronic Migraine: An Update on Physiology, Imaging, and the Mechanism of Action of Two Available Pharmacologic Therapies. Headache 2017; 57: 109-125.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Viana M,
    2. De Icco R,
    3. Allena M,
    4. Sances G,
    5. Højland JR,
    6. Katsarava Z, et al.
    Clinical subtypes of medication overuse headache - Findings from a large cohort. Headache 2019; 59: 1481-1491.
    OpenUrl
  9. 9.↵
    1. Lundqvist C,
    2. Gossop M,
    3. Russell MB,
    4. Straand J,
    5. Kristoffersen ES.
    Severity of analgesic dependence and medication-overuse headache. J Addict Med 2019; 13: 346-353.
    OpenUrl
  10. 10.↵
    1. Schwedt TJ,
    2. Buse DC,
    3. Argoff CE,
    4. Reed ML,
    5. Fanning KM,
    6. Hussar CR, et al.
    Medication overuse and headache burden: results from the CaMEO Study. Neurol Clin Pract 2021; 11: 216-226.
    OpenUrlAbstract/FREE Full Text
  11. 11.
    1. Stovner LJ,
    2. Nichols E,
    3. Steiner TJ,
    4. Abd-Allah F,
    5. Abdelalim A,
    6. Al-Raddadi RM, et al.
    Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018; 17: 954-976.
    OpenUrlCrossRefPubMed
  12. 12.
    1. Bottiroli S,
    2. Allena M,
    3. Sances G,
    4. De Icco R,
    5. Avenali M,
    6. Fadic R, et al.
    Changes in anxiety and depression symptoms associated to the outcome of MOH: A post-hoc analysis of the Comoestas Project. Cephalalgia 2018; 38: 646-654.
    OpenUrl
  13. 13.↵
    1. Vandenbussche N,
    2. Paemeleire K,
    3. Katsarava Z.
    The many faces of medication-overuse headache in clinical practice. Headache 2020; 60: 1021-1036.
    OpenUrl
  14. 14.↵
    1. Green A,
    2. Gu P,
    3. De Felice M
    4. Dodick D,
    5. Ossipov M,
    6. Porreca F.
    Increased susceptibility to cortical spreading depression in an animal model of medication-overuse headache. Cephalalgia 2014; 34: 594-604.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Vandenbussche N,
    2. Laterza D,
    3. Lisicki M,
    4. Lloyd J,
    5. Lupi C,
    6. Tischler H, et al.
    Medication-overuse headache: a widely recognized entity amidst ongoing debate. J Headache Pain 2018; 19: 50.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Schwedt TJ,
    2. Chong CD.
    Medication overuse headache: pathophysiological insights from structural and functional brain MRI research. Headache 2017; 57: 1173-1178.
    OpenUrl
  17. 17.↵
    1. Andreou AP,
    2. Edvinsson L.
    Mechanisms of migraine as a chronic evolutive condition. J Headache Pain 2019; 20: 117.
    OpenUrlPubMed
  18. 18.↵
    1. Diener HC,
    2. Dodick D,
    3. Evers S,
    4. Holle D,
    5. Jensen RH,
    6. Lipton RB, et al.
    Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurol 2019; 18: 891-902.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Cargnin S,
    2. Viana M,
    3. Sances G,
    4. Tassorelli C,
    5. Terrazzino S.
    A systematic review and critical appraisal of gene polymorphism association studies in medication-overuse headache. Cephalalgia 2018; 38: 1361-1373.
    OpenUrl
  20. 20.↵
    1. Mitsikostas DD,
    2. Paemeleire K
    1. Katsarava Z.
    Medication-overuse headache (MOH). In: Mitsikostas DD, Paemeleire K, editors. Pharmacological Management of Headaches. Headache. Cham (China): Springer; 2016. https://doi.org/10.1007/978-3-319-19911-5_19
  21. 21.↵
    1. Pellesi L,
    2. Guerzoni S,
    3. Baraldi C,
    4. Cainazzo MM,
    5. Pini LA,
    6. Bellei E.
    Identification of candidate proteomic markers in the serum of medication overuse headache patients: An exploratory study. Cephalalgia 2020; 40: 1070-1078.
    OpenUrl
  22. 22.↵
    1. Kristoffersen ES,
    2. Straand J,
    3. Vetvik KG,
    4. Benth JS,
    5. Russell MB,
    6. Lundqvist C.
    Brief intervention for medication overuse headache in primary care. The BIMOH study: A double blind pragmatic cluster randomised parallel controlled trial. J Neurol Neurosurg Psychiatry 2015; 86: 505-512.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Scher AI,
    2. Rizzoli PB,
    3. Loder EW.
    Medication overuse headache: An entrenched idea in need of scrutiny. Neurol 2017; 89: 1296-1304.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Buse DC,
    2. Greisman JD,
    3. Baigi K,
    4. Lipton RB.
    Migraine Progression: A Systematic Review. Headache 2019; 59: 306-338.
    OpenUrl
  25. 25.↵
    1. Al Quliti KW.
    Prevalence of depressive symptoms and its correlates in primary headache patients with a history of head-neck trauma. Neurosciences (Riyadh) 2022; 27: 181-186.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Al-Quliti K.
    Stress and Its Correlates in Migraine-Headache Patients with a Family History of Migraine. Behavioral Sciences 2022; 12: 65.
    OpenUrl
  27. 27.↵
    1. Westergaard ML,
    2. Glümer C,
    3. Hansen EH,
    4. Jensen RH.
    Medication overuse, healthy lifestyle behaviour and stress in chronic headache: results from a population-based representative survey. Cephalalgia 2016; 36: 15-28.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Kristoffersen ES,
    2. Straand J,
    3. Russell MB,
    4. Lundqvist C.
    Lasting improvement of medication overuse headache after brief intervention—A long term follow up in primary care. Eur J Neurol 2017; 24: 883-891.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Diener HC,
    2. Antonaci F,
    3. Braschinsky M,
    4. Evers S,
    5. Jensen R,
    6. Lainez M, et al.
    European Academy of Neurology guideline on the management of medication-overuse headache. Eur J Neurol 2020; 27: 1102-1116.
    OpenUrlPubMed
  30. 30.↵
    1. Nielsen M,
    2. Carlsen LN,
    3. Munksgaard SB,
    4. Engelstoft IMS,
    5. Jensen Rn,
    6. Bendtsen L.
    Complete withdrawal is the most feasible treatment for medication-overuse headache: A randomized controlled open-lable trial. Eur J Pain 2019; 23: 1162-1170.
    OpenUrl
  31. 31.↵
    1. Grazzi L,
    2. Grignani E,
    3. D’Amico D,
    4. Sansone E,
    5. Raggi A.
    Is medication overuse drug specific or not? Data from a review of published literature and from an original study on Italian MOH patients. Curr Pain Headache Rep 2018; 22: 71.
    OpenUrl
  32. 32.↵
    1. Engelstoft IMS,
    2. Carlsen LN,
    3. Munksgaard SB,
    4. Nielsen M,
    5. Jensen RH,
    6. Bendtsen L.
    Complete withdrawal is the most feasible treatment for medication-overuse headache: A randomized controlled open-label trial. Eur J Pain 2019; 23: 1162-1170.
    OpenUrl
  33. 33.↵
    1. Westergaard ML,
    2. Lau CJ,
    3. Allesoe K,
    4. Gjendal ST,
    5. Jensen RH.
    Monitoring chronic headache and medication-overuse headache prevalence in Denmark. Cephalalgia 2020; 40: 6-18.
    OpenUrl
  34. 34.↵
    1. Raggi A,
    2. Giovannetti AM,
    3. Leonardi M,
    4. Sansone E,
    5. Schiavolin S,
    6. Curone M, et al.
    Predictors of 12-months relapse after withdrawal treatment in hospitalized patients with chronic migraine associated with medication overuse: A longitudinal observational study. Headache 2017; 57: 60-70.
    OpenUrl
  35. 35.↵
    1. Bottiroli S,
    2. Allena M,
    3. Sances G,
    4. De Icco R,
    5. Avenali M,
    6. Fadic R, et al.
    Psychological, clinical, and therapeutic predictors of the outcome of detoxification in a large clinical population of medication-overuse headache: A six-month follow-up of the COMOESTAS Project. Cephalalgia 2019; 39: 135-147.
    OpenUrl
  36. 36.↵
    1. Carlsen LN,
    2. Munksgaard SB,
    3. Jensen RH,
    4. Bendtsen L.
    Complete detoxification is the most effective treatment of medication-overuse headache: A randomized controlled open-label trial. Cephalalgia 2018; 38: 225-236.
    OpenUrl
  37. 37.↵
    1. Fischer MA,
    2. Jan A.
    Medication-overuse headache. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538150/
  38. 38.↵
    1. De Goffau MJ,
    2. Klaver ARE,
    3. Willemsen MG,
    4. Bindels PJ,
    5. Verhagen, AP.
    The effectiveness of treatments for patients with medication overuse headache; a systematic review and meta-analysis. J Pain 2016; 18: 615-627.
    OpenUrl
  39. 39.↵
    1. Carlsen LN,
    2. Munksgaard SB,
    3. Nielsen M,
    4. Engelstoft IMS,
    5. Westergaard ML,
    6. Bendsten L, et al.
    Comparison of 3 treatment strategies for medication overuse headache: A randomized clinical trial. JAMA Neurol 2020; 77: 1069-1078.
    OpenUrl
  40. 40.
    1. Diener HC,
    2. Marmura MJ,
    3. Tepper SJ,
    4. Cowan R,
    5. Starling AJ,
    6. Diamond ML, et al.
    Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2. Headache 2021; 61: 125-136.
    OpenUrl
  41. 41.↵
    1. Dodick D,
    2. Tepper SJ,
    3. Diener HC,
    4. Tassorelli C,
    5. Lukas S,
    6. Evers S, et al.
    Efficacy of erenumab in chronic migraine patients with medication overuse and prior preventive treatment failure [abstract]. Neurol 2019; 92: S38.002
    OpenUrl
  42. 42.↵
    1. Tepper SJ,
    2. Diener HC,
    3. Ashina M,
    4. Brandes JL,
    5. Friedman DI,
    6. Reuter U, et al.
    Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial. Neurol 2019; 92: e2309-e2320.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Caronna E,
    2. Gallardo VJ,
    3. Alpuente A,
    4. Torres-Ferrus M,
    5. Pozo-Rosich P.
    Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months. J Headache Pain 2021; 22: 120.
    OpenUrl
  44. 44.↵
    1. Holland PR,
    2. Saengjaroentham C,
    3. Sureda-Gibert P,
    4. Strother LC.
    Medication overuse headache: Divergent effects of new acute antimigraine drugs. Cephalalgia 2020; 40: 889-891.
    OpenUrl
  45. 45.↵
    1. Navratilova E,
    2. Behravesh S,
    3. Oyarzo J,
    4. Dodick DW,
    5. Banerjee P,
    6. Porreca F.
    Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache. Cephalalgia 2020; 40: 892-902.
    OpenUrl
  46. 46.↵
    1. Van Hoogstraten WS,
    2. MaassenVanDenBrink A.
    The need for new acutely acting antimigraine drugs: Moving safely outside acute medication overuse. J Headache Pain 2019; 20: 54.
    OpenUrl
  47. 47.↵
    1. Rau JC,
    2. Navratilova E,
    3. Oyarzo J,
    4. Johnson KW,
    5. Aurora SK,
    6. Schwedt TJ, et al.
    Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache. Cephalalgia 2020; 40: 903-912.
    OpenUrl
  48. 48.↵
    1. Silberstein S,
    2. Cohen JM,
    3. Seminerio MJ,
    4. Yang R,
    5. Ashina S,
    6. Katsarava Z.
    The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study. J Headache Pain 2020; 21: 114.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Related Articles

  • No related articles found.

Cited By...

  • No citing articles found.

More in this TOC Section

Similar Articles